Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests

MT Newswires Live03-25

Veracyte (VCYT) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.

The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.

The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.

The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.

Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522983543?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-26 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522983543","market":"sg","top_or_hot":-1,"title":"Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests","media":"MT Newswires Live","content":"<html><body><p> Veracyte (VCYT) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.</p><p>The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.</p><p>The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.</p><p>The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.</p><p>Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-26 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Veracyte (VCYT) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.</p><p>The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.</p><p>The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.</p><p>The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.</p><p>Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522983543","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522983543","pubTimestamp":1742937384,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Veracyte  late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc","BK4139":"生物科技"},"translate_title":"Veracyte癌症诊断平台显示出比血液测试更高的特异性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte (VCYT) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522983543"}